Revvity Fuels the Future of Cancer Science with New Research Solutions

Latest innovations unveiled at American Association for Cancer Research (AACR) Annual Meeting 2025 include image-guided injection system and other solutions advancing discoveries across cancer science

Revvity, Inc., is set to unveil the VivoJect™ Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Meeting 2025 in Chicago, April 25-30.

Paired with the Vega™ automated preclinical ultrasound system, the VivoJect system allows for real-time imaging and precise, nimble operation for researchers at a higher throughput compared to traditional techniques. It streamlines in vivo imaging workflows for applications such as tumor model creation, targeted drug delivery, gene therapy, stem cell research, and cardiac studies.

Revvity will also showcase a broad portfolio of solutions driving advancements in cancer research at its booth (#1200), including the PhenoVue™ DNA Damage Response Staining Kit, Harmony™ 5.3 and Phenologic.AI™ high-content image analysis software and over 120 cell line-derived oncology reference standards from its Mimix™ portfolio. BioLegend’s reagent innovations will also be on display, including the TotalSeq™ PhenoCyte, TotalSeq-A and -C Universal Cocktails, v2.0, LEGEND MAX™ High Sensitivity Mouse TNF-a and ELISA MAX™ Deluxe Set Human ICAM-1 kits.

“We’re bringing together cutting-edge science and innovative technology to support researchers working across the cancer science landscape, from early discovery to translational studies,” said Kevin Quick, vice president of platforms, life sciences. “Our solutions are designed to empower scientists across various stages of their research, whether that’s decoding cancer at its most basic, molecular level, or developing novel therapeutics used to treat it.”

Key Exhibits at AACR Annual Meeting 2025

Revvity’s booth will also feature:

• Cell analysis in 3D, and AI: Solutions include cell counters and image cytometers, cellular imaging reagents, microplates and analysis software, as well as high-content imaging instruments.
• Immunoassays: An extensive range of immunoassay technologies including multimode microplate readers and microplates, as well as assay kits and reagents.
• In vivo imaging: Instruments, reagents, software and related accessories to help accelerate drug development by tracking disease progression, evaluate efficacy, and assess toxicity.
• Genomic solutions: A wide range of solutions including the Pin-point™ base editing platform, OMNI™ sample homogenizers, liquid handling workstations and more.

More than 10 scientific posters authored or co-authored by Revvity employees will be on display. Among them is a poster produced in collaboration with a research team from Charles River Laboratories, which utilized Revvity’s Vega automated preclinical ultrasound system in a longitudinal study of the progression of graft versus host disease.

For further information on Revvity’s cancer research innovations and poster presentations at the AACR Annual Meeting 2025, visit booth #1200 or this link.

All Revvity offerings mentioned herein are for research use only, and not for use in diagnostic procedures.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422179798/en/